Figure 6 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer

Read full text Summarise with VIRAT
Authors: Charlie Chung, Brian Yueh, Santhilal Subhash, Onur Eskiocak, Aaron Nizam, Marissa G. Viola, Pascal Belleau, Ariel Kredentser, Arisa Kapedani, Alexander Krasnitz, Ken Simon, Werner Meier
+3 more Marina Frimer, Gary L. Goldberg, Semir Beyaz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

CAR-T cells demonstrate target-dependent activity in endometrial organoid. A, Representative images of coculture using a normal and two HGEC PDOs (low and high EGFR) without immune cells, with untransduced CD8 T cells (mock), or EGFR-CAR-T cells (55). Red and green fluorescence represent endometrial organoids and corresponding immune cells, respectively. Blue fluorescence represents active caspase-3 signals. Scale bar, 70 μm. B, Colocalization of the PDOs and corresponding immune cells over the time of imaging. Colocalization coefficient (R1) was calculated as described previously (26) and normalized to the initial time point. The area under the curve was used for statistical significance (ordinary t test). C, The end point viability of the PDO in the coculture measured by colocalization coefficient between the PDOs and caspase-3 signals. Colocalization coefficient was calculated as described previously (26) and normalized to no immune cell control (vehicle). Cas3, caspase-3. D, A schematic depicting the utilization of autologous PDO–immune coculture system. MSI-H, microsatellite instability–high; MSS, microsatellite stability. Ordinary one-way ANOVA (C) was used to calculate statistical significance (*, P < 0.05; **, P < 0.01; ***, P < 0.001).

Fields of Study & Subjects

CAR-T cell therapy research Cancer Immunotherapy and Biomarkers Endometrial and Cervical Cancer Treatments

Publication details

Publication date
25 March 2026
Language
EN